Modulation of in vitro immune reactions by platelet activating factor and a platelet activating factor antagonist
β Scribed by Bryan M. Gebhardt; Pierre Braquet; Haydee Bazan; Nicolas Bazan
- Publisher
- Elsevier Science
- Year
- 1988
- Tongue
- English
- Weight
- 679 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0162-3109
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The failure of normal human platelets to aggregate in response to platelet activating factor (PAF) has not been previously observed. We report here the first case of a patient whose platelets did not aggregate to PAF on multiple occasions.
-propoxy-S(N'-butyl-N'-hydroxyureidyl)phenyl]-S-(3,4.5-trimethoxyphenyl)tetrahydrofuran, was synthesized and was found to antagonize PAP receptor binding and inhibit S-lipoxygenase activity both in vitro and in vivo.
## Abstract Plateletβactivating factor (1β__O__βalkylβ2βacetylβ__sn__βglyceroβ3βphosphorylcholine; PAF) is a very potent phospholipid, which has been demonstrated to stimulate smooth muscle and change vascular permeability. PAF has been detected in the rabbit preimplantation uterine endometrium and